Skip to main content
MedPathMedPath Home
Clinical Trials/jRCT2031230429
jRCT2031230429
Active, not recruiting
Not Applicable

ONO-7475-04:A Phase1 study to examine tolerability and safety of ONO-7475 in combination with ONO-4538 and gemcitabine plus nab-paclitaxel (GnP), the standard of care, and safety of ONO-7475 in combination with GnP in patients with metastatic pancreatic cancer as first-line treatment

Ono Pharmaceutical Co.,LTD0 sites87 target enrollmentDecember 6, 2023
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Ono Pharmaceutical Co.,LTD
Enrollment
87
Primary Endpoint
-
Status
Active, not recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
jrct.mhlw.go.jp
Start Date
December 6, 2023
End Date
TBD
Last Updated
last year
Study Type
Interventional
Study Design
Parallel Assignment
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1.Patient with metastatic pancreatic cancer
  • •2.Patients have an ECOG performance status of 0 to 1
  • •3.Patients with a life expectancy of at least 6 months

Exclusion Criteria

  • •1.Patients are unable to swallow oral medications
  • •2.Patients with severe complication

Outcomes

Primary Outcomes

-

Safety and tolerability

Similar Trials

Completed
Phase 1
Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IIIC Non-Small Cell Lung CancerStage IV Non-small Cell Lung CancerRecurrent Non-Small Cell Lung CancerEGFR Mutation-Related Tumors
NCT06525246Ono Pharmaceutical Co. Ltd78
Active, not recruiting
Phase 1
A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic CancerMetastatic Pancreatic Cancer
NCT06532331Ono Pharmaceutical Co. Ltd87
Completed
Phase 2
Study of ONO-8577 in Patients With Overactive BladderOveractive Bladder
NCT03106623Ono Pharmaceutical Co. Ltd207
Unknown
Phase 1
ONO-6950 Phase 1 StudyAsthma
JPRN-jRCT2080221601ONO PHARMACEUTICAL CO.,LTD.52
Active, not recruiting
Phase 1
ONO-7475-03 : ONO-7475 Phase 1 StudyEGFR mutated, stage IIIB/IIIC/IV or recurrent, NSCLC, which is unsuitable for radical irradiation
JPRN-jRCT2051210045Osawa Masahiro75